IQVIA earnings for the third quarter of 2026 included revenue of $4,428 million, up 8% from a year earlier and above the $4,366 million analyst estimate. The clinical research and healthcare data provider reported the results on October 27.
Key Takeaways
- GAAP diluted earnings per share were $2.10, while adjusted diluted earnings per share were $3.34.
- Revenue grew 8.7% in Research and Development Solutions and 6.9% in Commercial Solutions.
- Quarterly free cash flow fell to $667 million from $772 million a year earlier.
IQVIA earnings and cash flow
GAAP net income rose to $350 million from $332 million in the third quarter of 2025. Adjusted EBITDA increased to $1,032 million from $949 million.
GAAP diluted earnings per share were $2.10. An analyst estimate was $2.18, although the available information does not specify the estimate’s accounting basis. IQVIA also reported adjusted diluted earnings per share of $3.34, a separate measure from GAAP earnings.
Cash generated from operating activities totaled $825 million. Free cash flow declined year over year despite the increases in revenue and net income.
| Item | Details |
|---|---|
| Revenue | Q3 2026: $4,428 million; Q3 2025: $4,100 million |
| GAAP net income | Q3 2026: $350 million; Q3 2025: $332 million |
| Adjusted EBITDA | Q3 2026: $1,032 million; Q3 2025: $949 million |
| Free cash flow | Q3 2026: $667 million; Q3 2025: $772 million |
Segment growth and backlog adjustment
Research and Development Solutions provides outsourced clinical development services, while Commercial Solutions supplies healthcare data, analytics and technology. Both segments increased revenue from the prior-year quarter.
Chief Executive Ari Bousbib said multiple demand indicators continued to validate a strengthening market environment. IQVIA also made an approximately $2.1 billion adjustment to its backlog; the available information does not specify the adjustment’s direction or underlying reason.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
Comments
Be respectful. No spam, impersonation or private credentials. Ordinary posts and comments appear immediately; suspicious links are held for review.
Please wait…